Dec.—Personalized diagnostics company LineaGen raised $5.8mm in its Series A financing led by vSpring Capital and Sanderling Biomedical Ventures with additional participation from Mesa Verde Partners.
The money will help launch the company and enable the development of its biomarker discovery platform. LineaGen's initial areas of interest include autism, multiple sclerosis, osteoporosis, and chronic obstructive pulmonary...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?